Search Results - "SCOTT, Edwina N"

Prolonged Biologically Active Colonic Tissue Levels of Curcumin Achieved After Oral Administration—A Clinical Pilot Study Including Assessment of Patient Acceptability by IRVING, Glen R. B, HOWELLS, Lynne M, HEMINGWAY, David, MILLER, Andrew S, BROWN, Karen, GESCHER, Andreas J, STEWARD, William P, SALE, Stewart, KRALJ-HANS, Ines, ATKIN, Wendy S, CLARK, Susan K, BRITTON, Robert G, JONES, Donald J. L, SCOTT, Edwina N, BERRY, David P

“…Curcumin, the main constituent of turmeric, is suspected to possess cancer chemopreventive properties. Pharmacokinetic and pharmacodynamic parameters have been…”
Get full text

Distribution and metabolism of [14C]-resveratrol in human prostate tissue after oral administration of a “dietary-achievable” or “pharmacological” dose: what are the implications for anticancer activity? by Cai, Hong, Scott, Edwina N, Britton, Robert G, Parrott, Emma, Ognibene, Ted J, Malfatti, Michael, Khan, Masood, Steward, William P, Brown, Karen

“…The dietary polyphenol resveratrol prevents various malignancies in preclinical models, including prostate cancer. Despite attempts to translate findings to…”
Get full text

Vatalanib: the clinical development of a tyrosine kinase inhibitor of angiogenesis in solid tumours by Scott, Edwina N, Meinhardt, Gerold, Jacques, Christian, Laurent, Dirk, Thomas, Anne L

“…The licensing of bevacizumab in patients with metastatic colorectal cancer has fueled research in angiogenesis. Vatalanib (PTK787/ZK 222584), a potent oral…”
Get more information

Development of dietary phytochemical chemopreventive agents: biomarkers and choice of dose for early clinical trials by Scott, Edwina N, Gescher, Andreas J, Steward, William P, Brown, Karen

“…In view of safety concerns surrounding the use of pharmaceuticals such as nonsteroidal anti-inflammatory drugs and tamoxifen as cancer chemopreventive agents,…”
Get full text

A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI™), in patients with advanced solid tumours by Scott, Edwina N., Thomas, Anne L., Molife, L. Rhoda, Ahmed, Samreen, Blagden, Sarah, Fong, Peter C., Kowal, Kristin, McCoy, Candice, Wiesinger, Herbert, Steward, Will, De Bono, Johann

“…Purpose The toxicities, pharmacokinetics and recommended dose of oral once daily ZK 304709, a novel multi-targeted growth inhibitor (MTGI ™ ) with activity…”
Get full text

Surgical bypass vs. endoscopic stenting for pancreatic ductal adenocarcinoma by Scott, Edwina N., Garcea, Giuseppe, Doucas, Helena, Steward, Will P., Dennison, Ashley R., Berry, David P.

“…The majority of patients with pancreatic cancer are non-resectable and jaundiced at presentation. Methods of palliation in such patients with locally advanced…”
Get full text